Form 4: Lexeo Therapeutics Director, Paula Cholmondeley, Reports Stock Option Grant

Director Paula Cholmondeley reports the acquisition of stock options in Lexeo Therapeutics.

Summary

• Paula Cholmondeley, a director of Lexeo Therapeutics, filed a Form 4 disclosing a transaction involving derivative securities.
• On June 25, 2024, Cholmondeley acquired stock options for 18,000 shares of Lexeo Therapeutics common stock at an exercise price of $16.87.
• The options vest on the earlier of June 25, 2025, or the date of the Issuer's next annual stockholders meeting, contingent upon continuous service.
• Cholmondeley also granted power of attorney to Jenny Robertson, Youjin Choi, Jessica McBride, Carole Rosenberg and James Reilly to handle Section 16 filings.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to executive compensation. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting of the options is tied to the director's continued service and the company's annual stockholder meeting.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly typical, aligning with industry norms for incentivizing long-term commitment.
• Comparable companies like BioMarin Pharmaceutical and Sarepta Therapeutics also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially incentivizing decisions that increase shareholder value.

Key Dates